Methods for biosynthesising hydrocarbons from a gaseous substrate in non-naturally occurring acetogens as well as non-naturally occurring acetogens for production of hydrocarbons are provided.

The disclosure provides methods for selecting watermelon plants for genetic elements on chromosome 2 and 6 which genetic elements predict the average seed size produced in the fruits of said plants and watermelon plants and plant parts comprising modifications in the tomato-seed size gene (Ts-gene) on chromosome 2, and methods of producing seeds and plants.

A copolymer comprising: a hydroxycarboxylic acid (A) having a hydroxy group only at a 2-position; and a hydroxycarboxylic acid (B) having a hydroxy group at a position other than a 2-position, and having a homopolymer segment composed of one hydroxycarboxylic acid selected from the group consisting of the hydroxycarboxylic acid (A) and the hydroxycarboxylic acid (B), and a copolymer segment containing at least two hydroxycarboxylic acids selected from the group consisting of the hydroxycarboxylic acid (A) and the hydroxycarboxylic acid (B).

The technology described herein is directed to engineered chemoautotrophic bacteria and methods of producing sustainable biomolecules. In several aspects, described herein are engineered bacteria and corresponding methods, compositions, and systems for the production of products such as polyhydroxyalkanoates (PHA), sugar feedstocks, and lipochitooligosaccharide (LCO) fertilizers.

Polyketide synthases are engineered to produce lactones. In the first module, an acyltransferase is swapped and in the second module a reductive loop is swapped. With another acyltransferase swap in the second module, we can programmably produce the non-methylated delta lactone.

Disclosed herein, in some embodiments, are vectors encoding biosynthetic enzymes from gut microbiome-derived bacterium (e.g., Clostridia enzymes), engineered cells comprising the vectors, and methods of using biosynthetic enzymes from gut microbiome-derived bacterium (e.g., Clostridia enzymes) to produce fatty acid amides.

The present invention encompasses the recognition that identification of alternative means to block RAS oncogenic signaling may be required for developing novel cancer therapies. Among other things, the present invention encompasses the recognition that targeting RAS palmitoylation can achieve effective therapy for RAS-related cancers. Furthermore, the present invention encompasses the recognition that reduction of ZDHHC9 level and/or activity can significantly reduce palmitoylation level of Ras protein. Among other things, the present invention encompasses the recognition that identification of agents that modulate expression and/or activity of ZDHHC9 can reduce palmitoylation level of Ras protein. In some embodiments, the present invention provides methods of treating a subject suffering from cancer by administering ZDHHC9 inhibition therapy.

The invention relates to a hybrid proteinaceous molecule comprising at least two proteins capable of inhibiting the activity of at least one antibiotic, the proteins each having different biochemical properties and being bonded to one another. The hybrid proteinaceous molecule inhibits the activity of a least one antibiotic in order to reduce the intestinal side effects of antibiotics, such as severe diarrhoea caused by the antibiotics, and nosocomial infections secondary to parenteral antibiotic therapy.

This application provides the first observation of methylmalonylation/malonylation in organic acidemias (OAs), such as methylmalonic acidemia (MMA) and propionic acidemia (PA), which results in modification of enzymes in key pathways dysregulated in OAs, including sirtuin 5 (SIRT5). Hyperacylation of SIRT5 prevents it from de-acylating CPS1 (including removing methymalonyllation), which prevents activation of CPS1 and likewise, inhibits a key component of the glycine cleavage system, GCSH. Based on these observations, provided herein is a mutant form of SIRT5 containing four mutated lysines that cannot accept acyl groups, methods of its use for treating OA patients, and kits.

The present invention relates to a method of preparing a gene cluster construct including a plurality of genes encoding a multi-modular biosynthetic enzyme, the method including (A) a step of preparing a plurality of DNA fragments which are capable of reconstructing the gene cluster construct and have structures that can be ligated to each other and (B) a step of ligating the plurality of DNA fragments prepared in the step (A) to each other by mixing the plurality of DNA fragments in a solution to obtain the gene cluster construct.